MBX Biosciences, Inc. Common Stock (MBX NASDAQ) stock market data APIs
$10.7097
0.69(6.4%)
as of June 27, 2025
Try our APIs with
free plan!
MBX Biosciences, Inc. Common Stock Financial Data Overview
MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is MBX 2109, a parathyroid hormone peptide prodrug, which is in Phase 2 clinical trial for the treatment of chronic hypoparathyroidism. The company is also developing MBX 1416, a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist that is in Phase 1 clinical trial a potential therapy for post-bariatric hypoglycemia, a chronic complication of bariatric surgery. In addition, it is developing MBX 4291, a lead obesity product candidate, which is in investigational new drug-enabling studies for the treatment of obesity and co-morbidities. The company was founded in 2018 and is based in Carmel, Indiana.
Prev. Close
10.7097
Open
11.398
High
11.5941
Low
10.2912
52 wk Range
4.807-27.5
Market Cap
676 M
Shares Outstanding
31 854 K
EPS
-0.7147
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get MBX Biosciences, Inc. Common Stock data using free add-ons & libraries
Get MBX Biosciences, Inc. Common Stock Fundamental Data
MBX Biosciences, Inc. Common Stock Fundamental data includes:
- Net Revenue:
- EBITDA: -50 717 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-05-12
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
MBX Biosciences, Inc. Common Stock News
New
MBX Prepares For Phase 1 Trial In Q3 With IND Filing For Obesity Candidate MBX 4291
(RTTNews) - MBX Biosciences, Inc. (MBX), announced Monday that it has submitted an Investigational New Drug application to the U.S. Food and Drug Administration for MBX 4291, its long-acting GLP-1/GIP...
MBX Biosciences submits IND for once-monthly obesity treatment
CARMEL, Ind. - MBX Biosciences, Inc. (NASDAQ:MBX), a clinical-stage biopharmaceutical company with a market capitalization of $347 million, has submitted an Investigational New Drug (IND) application ...
MBX Biosciences to Present at the American Diabetes Association 85th Scientific Sessions
CARMEL, Ind., June 10, 2025 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide th...
MBX Biosciences to Participate in the 24th Annual Needham Virtual Healthcare Conference
CARMEL, Ind., March 26, 2025 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide t...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
